TA 01

立即咨询

TA 01

本产品不向个人销售，仅用作科学研究，不用于任何人体实验及非科研性质的动物实验。

CAS NO:	1784751-18-3
包装:	10mg, 25mg, 50mg

包装与价格：

产品名称

TA-01
TA01

产品介绍

TA-01是一种有效的CK1和p38 MAPK抑制剂，对CK1ε，CK1δ和p38 MAPK的IC50值分别为6.4 nM，6.8 nM和6.7 nM。当在5μM下施用时，TA-01抑制剂抑制心脏发育。TA-01显示所有测试的中胚层标记物和心脏前标志物Isl-1的表达降低。

细胞实验
细胞系	Human pluripotent stemcell lines HES-3 and H7
方法	Human pluripotent stemcell lines HES-3 and H7 were seeded at 2.5 × 10⁶cells/12-ULA well in BSFS medium with cell line optimized concentrations of CHIR99021 for 24 h (Supplemental Fig. S7). Thereafter the 2,4,5-trisubstituted azoles or IWP-2 or IWR-1 were added at a concentration of 5 μM (2.5 μM for IWR-1) either from 1-8 days or from 4-8 days. Dissociated EBs showed an average of 50–60% NKX2-5⁺cells on day 11 when either 2,4,5-trisubstituted azoles, IWP-2 and IWR-1 were applied from 4-8 days i.e. at the post mesoderm stage. In comparison to premesoderm treatment only HES-3 showed high cardiomyocyte expansion fold with SB203580 (days 1-8) (Fig. 3A). To confirm that 2,4,5-trisubstituted azoles had no negative impact on cell viability, we analyzed the cell growth kinetics. EBs treated with IWP-2 and IWR-1 generated significantly fewer cells compared to 2,4,5-trisubstituted azoles in both cell lines (Fig. 3A). Metabolismrates of EBs measured with MTT showed an increase with TA-01 but not with IWR-1 and IWP-2 during the compound induction period.
浓度	5 μM
处理时间	-

动物 A (mg/kg) = 动物 B (mg/kg) ×	动物 B的K_m系数
	动物 A的K_m系数

例如，依据体表面积折算法，将化合物用于小鼠的剂量20 mg/kg 换算成大鼠的剂量，需要将20 mg/kg 乘以小鼠的K_m系数（3），再除以大鼠的K_m系数（6），得到化合物用于大鼠的等效剂量为10 mg/kg。

以下数据基于产品分子量，对于特殊产品，请参照COA中的储备液配制条件和说明进行操作。

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	2.8464 mL	14.232 mL	28.4641 mL
5 mM	0.5693 mL	2.8464 mL	5.6928 mL
10 mM	0.2846 mL	1.4232 mL	2.8464 mL